PuSH - Publikationsserver des Helmholtz Zentrums München: Kombination Radio(chemo)therapie beim Lungenkarzinom

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Kraus, K.M. ; Eichner, R.* ; Combs, S.E.

Kombination Radio(chemo)therapie beim Lungenkarzinom – Nebenwirkungsmanagement.

Combined chemoradiotherapy in lung cancer—Management of side effects.

Best Pract. Onkol. 18, 496-507 (2023)

Verlagsversion

DOI

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Simultaneous chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC) in stage III and for limited stages of small cell lung cancer (SCLC) and nonoperability. The side effects depend on the cytotoxic agents employed, the radiotherapeutic parameters and the patient characteristics. This article summarizes and discusses the management strategies for frequent and relevant side effects of CRT of lung cancer. The chemotherapy mostly includes a highly emetogenic platinum derivative. Therefore, prophylaxis of chemotherapy-associated nausea and vomiting with serotonin 5‑hydroxytryptamine‑3 (5-HT3) and neurokinin 1 (NK1) receptor antagonists and dexamethasone is an essential element of peritherapeutic management. The management of likewise primary chemotherapy-induced hematologic side effects depends on the severity and the affected blood cell lineage and involves growth factors and blood transfusions. In contrast, radiotherapy-induced alterations, especially of the lungs and esophagus can mostly not be causally treated but are treated symptomatically. The prophylaxis and treatment of the broad spectrum of side effects of CRT of lung cancer should be based on a thorough evaluation of the severity of symptoms, the treatment efficacy and associated risks.

Impact Factor

Scopus SNIP

Altmetric

0.000

0.012